BR0010823A - Stability adjuvant, optimized biocompatibility (sba) to enhance the humoral and cellular immune response - Google Patents

Stability adjuvant, optimized biocompatibility (sba) to enhance the humoral and cellular immune response

Info

Publication number
BR0010823A
BR0010823A BR0010823-5A BR0010823A BR0010823A BR 0010823 A BR0010823 A BR 0010823A BR 0010823 A BR0010823 A BR 0010823A BR 0010823 A BR0010823 A BR 0010823A
Authority
BR
Brazil
Prior art keywords
sba
immune response
cellular immune
humoral
enhance
Prior art date
Application number
BR0010823-5A
Other languages
Portuguese (pt)
Inventor
Rainer Helmut Mueller
Nikolaus Grubhofer
Carsten Olbrich
Original Assignee
Pharmasol Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmasol Gmbh filed Critical Pharmasol Gmbh
Publication of BR0010823A publication Critical patent/BR0010823A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants

Abstract

Patente de Invenção: "ADJUVANTE DE ESTABILIDADE, BIOCOMPATIBILIDADE OTIMIZADA (SBA) PARA REALçAR A RESPOSTA IMUNE HUMORAL E CELULAR". A invenção refere-se a um adjuvante de estabilidade e biocompatibilidade otimizada (SBA) para realçar a resposta imune humoral e celular no caso de injeção junto com um ou mais antígenos. O adjuvante consiste em partículas com base em lipídeos sólidos ou misturas de lipídeos sólidos. Aplicações possíveis incluem a produção de vacinas mais eficazes e melhor toleradas, vacinações de seres humanos e animais e também a produção de anticorpos. Através da escolha de tamanho de partícula, carga de partícula e propriedades da superfície, a intensidade da resposta imune pode ser especificamente modulada e adicionalmente ajustada para ser específica das espécies. Outros adjuvantes, por exemplo adjuvantes moleculares tal como GMDP podem ser adicionados ao SBA, adicionalmente aumentando a resposta imune celular. O SBA é eficaz e económico, mais simples para manuseio do que os produtos existentes e é bem tolerado in vivo.Invention Patent: "STABILITY ASSISTANT, OPTIMIZED BIOCOMPATIBILITY (SBA) TO ENHANCE THE HUMORAL AND CELLULAR IMMUNE RESPONSE". The invention relates to an adjuvant of stability and optimized biocompatibility (SBA) to enhance the humoral and cellular immune response in the case of injection together with one or more antigens. The adjuvant consists of particles based on solid lipids or mixtures of solid lipids. Possible applications include the production of more effective and better tolerated vaccines, vaccinations of humans and animals and also the production of antibodies. Through the choice of particle size, particle load and surface properties, the intensity of the immune response can be specifically modulated and further adjusted to be species specific. Other adjuvants, for example molecular adjuvants such as GMDP can be added to the SBA, further increasing the cellular immune response. SBA is effective and economical, simpler to handle than existing products and is well tolerated in vivo.

BR0010823-5A 1999-05-20 2000-05-19 Stability adjuvant, optimized biocompatibility (sba) to enhance the humoral and cellular immune response BR0010823A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19923256 1999-05-20
PCT/EP2000/004565 WO2000071154A2 (en) 1999-05-20 2000-05-19 Stability, biocompatibility optimized adjuvant (sba) for enhancing humoral and cellular immune response

Publications (1)

Publication Number Publication Date
BR0010823A true BR0010823A (en) 2002-03-05

Family

ID=7908697

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0010823-5A BR0010823A (en) 1999-05-20 2000-05-19 Stability adjuvant, optimized biocompatibility (sba) to enhance the humoral and cellular immune response

Country Status (11)

Country Link
EP (1) EP1183045A2 (en)
JP (1) JP2003500365A (en)
KR (1) KR20020012221A (en)
AU (2) AU5214200A (en)
BR (1) BR0010823A (en)
CA (1) CA2373239A1 (en)
DE (1) DE10024788A1 (en)
MX (1) MXPA01011660A (en)
TR (1) TR200103333T2 (en)
WO (2) WO2000071154A2 (en)
ZA (1) ZA200109147B (en)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5214200A (en) * 1999-05-20 2000-12-12 Pharmasol Gmbh Stability, biocompatibility optimized adjuvant (sba) for enhancing humoral and cellular immune response
US9006175B2 (en) 1999-06-29 2015-04-14 Mannkind Corporation Potentiation of glucose elimination
WO2003080149A2 (en) 2002-03-20 2003-10-02 Mannkind Corporation Inhalation apparatus
ATE545434T1 (en) * 2003-10-23 2012-03-15 Novartis Vaccines & Diagnostic STABILIZED COMPOSITIONS
FR2873386B1 (en) 2004-07-22 2011-01-14 Agence Francaise De Securite Sanitaire Des Aliments Afssa VACCINE COMPOSITION AGAINST RHODOCOCCUS EQUI
JP5078014B2 (en) 2004-08-20 2012-11-21 マンカインド コーポレイション Catalytic reaction of diketopiperazine synthesis.
MX2007002189A (en) 2004-08-23 2008-01-11 Mannkind Corp Diketopiperazine salts, diketomorpholine salts or diketodioxane salts for drug delivery.
US7803404B2 (en) * 2005-09-14 2010-09-28 Mannkind Corporation Method of drug formulation based on increasing the affinity of active agents for crystalline microparticle surfaces
IN2015DN00888A (en) 2006-02-22 2015-07-10 Mannkind Corp
KR101933816B1 (en) 2008-06-13 2019-03-29 맨카인드 코포레이션 A dry powder inhaler and system for drug delivery
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
WO2009155581A1 (en) 2008-06-20 2009-12-23 Mannkind Corporation An interactive apparatus and method for real-time profiling of inhalation efforts
TWI494123B (en) 2008-08-11 2015-08-01 Mannkind Corp Use of ultrarapid acting insulin
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
PL2405963T3 (en) 2009-03-11 2014-04-30 Mannkind Corp Apparatus, system and method for measuring resistance of an inhaler
BRPI1013154B1 (en) 2009-06-12 2020-04-07 Mannkind Corp MICROPARTICLES OF DICETOPIPERAZINE WITH SPECIFIC SURFACE AREAS DEFINED, DRY POWDER UNDERSTANDING THE REFERRED MICROPARTICLES, METHOD FOR FORMATION OF THE REFERENCESMICROPARTICLES AND THE FORMATION OF MICROPARTYSTEMS
CA2778698A1 (en) 2009-11-03 2011-05-12 Mannkind Corporation An apparatus and method for simulating inhalation efforts
MX359281B (en) 2010-06-21 2018-09-21 Mannkind Corp Dry powder drug delivery system and methods.
MX353285B (en) 2011-04-01 2018-01-05 Mannkind Corp Blister package for pharmaceutical cartridges.
WO2012174472A1 (en) 2011-06-17 2012-12-20 Mannkind Corporation High capacity diketopiperazine microparticles
IN2014DN03093A (en) 2011-10-24 2015-05-15 Mannkind Corp
AU2013256565B2 (en) 2012-04-30 2015-12-03 Ossur Hf Prosthetic device, system and method for increasing vacuum attachment
SG10201605800UA (en) 2012-07-12 2016-09-29 Mannkind Corp Dry powder drug delivery system and methods
WO2014066856A1 (en) 2012-10-26 2014-05-01 Mannkind Corporation Inhalable influenza vaccine compositions and methods
KR102499439B1 (en) 2013-03-15 2023-02-13 맨카인드 코포레이션 Microcrystalline diketopiperazine compositions and methods
CA2918369C (en) 2013-07-18 2021-06-29 Mannkind Corporation Heat-stable dry powder pharmaceutical compositions and methods
WO2015021064A1 (en) 2013-08-05 2015-02-12 Mannkind Corporation Insufflation apparatus and methods
US10307464B2 (en) 2014-03-28 2019-06-04 Mannkind Corporation Use of ultrarapid acting insulin
US10561806B2 (en) 2014-10-02 2020-02-18 Mannkind Corporation Mouthpiece cover for an inhaler
WO2017097783A1 (en) * 2015-12-08 2017-06-15 Glaxosmithkline Biologicals S.A. Novel adjuvant formulations

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19745950A1 (en) * 1997-10-17 1999-04-22 Dds Drug Delivery Service Ges Drug carrier particle for site specific drug delivery, especially to CNS
WO2000006120A1 (en) * 1998-07-31 2000-02-10 Korea Institute Of Science And Technology Lipid emulsion and solid lipid nanoparticle as a gene or drug carrier
AU5214200A (en) * 1999-05-20 2000-12-12 Pharmasol Gmbh Stability, biocompatibility optimized adjuvant (sba) for enhancing humoral and cellular immune response

Also Published As

Publication number Publication date
AU5214200A (en) 2000-12-12
JP2003500365A (en) 2003-01-07
CA2373239A1 (en) 2000-11-30
KR20020012221A (en) 2002-02-15
AU5809100A (en) 2000-12-12
DE10024788A1 (en) 2000-11-23
ZA200109147B (en) 2002-05-08
TR200103333T2 (en) 2002-04-22
EP1183045A2 (en) 2002-03-06
WO2000071077A2 (en) 2000-11-30
MXPA01011660A (en) 2004-04-05
WO2000071154A2 (en) 2000-11-30
WO2000071154A3 (en) 2001-06-28

Similar Documents

Publication Publication Date Title
BR0010823A (en) Stability adjuvant, optimized biocompatibility (sba) to enhance the humoral and cellular immune response
ATE229978T1 (en) HELICOBACTER PROTEINS AND VACCINES
ATE149841T1 (en) VACCINES AGAINST CANCER AND INFECTIOUS DISEASES
ATE435661T1 (en) COMPOSITIONS CONTAINING ADJUVANT QS-21 WITH POLYSORBATE OR CYCLODEXTRIN AS AID
NZ505877A (en) Oral delivery of nucleic acid vaccines by particulate complexes
HU9904549A (en) Vaccines
PT1135166E (en) CONJUGATES OF HAPTEN-VEHICLE FOR THE TREATMENT AND PREVENTION OF THE NICOTINE DEPENDENCE
DK1140165T3 (en) Improved adjuvant compositions based on saponin and associated methods
ITFI920052A1 (en) PROTEIN EXTRACTED FROM HELICOBACTER PYLORI CYTOTOXIC STRAINS, GENE THAT EXPRESSES IT, USE OF PROTEIN AS VACCINE OR DIAGNOSTIC.
NO20004972L (en) Derivatives of pneumococcal choline binding proteins for vaccines
ATE411043T1 (en) PROCEDURE OF DNA VACCINATION
BR0314373A (en) Stable immunogenic product for the induction of antibodies to one or more antigenic proteins in a subject, pharmaceutical, immunogenic and vaccine compositions and process of preparation of an immunogenic product
ATE501726T1 (en) COMPOSITION WITH IMMUNOGENIC MICROPARTICLES
ATE270707T1 (en) ENTEPNEUMOVIRUS AND CORRESPONDING VACCINE
EP1964573A3 (en) Method of inducing and/or enhancing an immune response to tumor antigens
BR0208041A (en) Modified interferon beta with reduced immunogenicity
DK0686030T3 (en) Microparticles loaded with antigen and pharmaceutical compositions containing these microparticles
WO2000012122A3 (en) Low-molecular fragments of hyaluronic acid for the preparation of vaccines
BR9807332A (en) Leishmania antigens for use in the therapy and diagnosis of leishmaniasis
BRPI0409321A (en) antigen hybrid, competition and method for inducing an immune response to an infectious agent or tumor antigen, method for treating an infectious disease or cancer, and, peptide
BR0303362A (en) Composition and method for enhancing an immune response in an animal, method for distributing a load protein in an animal cell, genetically modified living cell, and method for constructing a fusion protein for improving an immune response in an animal
AR045416A1 (en) HUMAN LYMPHOCYTE COADYUVANT FOR VACCINES
NO20041564L (en) Infectious salmon anemia virus vaccine
BR0207020A (en) Reduced immunogenicity modified granulocyte colony stimulating factor (g-csf)
DE68917138T2 (en) TOLERANCE INDUCTION TO A FOREIGNANT.

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A, 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 1962 DE 12/08/2008.